Treatment with pioglitazone induced significant, reversible mitral regurgitation
Open Access
- 30 April 2008
- journal article
- case report
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 7 (1) , 12
Abstract
There has in recent years been great concern about possible cardiac side effects of thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.Keywords
This publication has 4 references indexed in Scilit:
- Thiazolidinediones and Heart FailureDiabetes Care, 2007
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiographyJournal of the American Society of Echocardiography, 2003
- Clinical Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Left Ventricular Filling PressuresCirculation, 2000